Christopher J Joyce Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 day, 11 hours ago
Christopher J Joyce has an estimated net worth of at least $10.5 million*, as of March 18, 2026. They own 348,589 shares of ALHC stock. They have sold 436,672 shares of ALHC stock since 2021, for an estimated $4.3 million.
Christopher J Joyce $ALHC SEC Form 4 Insider Trading
Christopher J Joyce has filed a total of 28 insider trades in $ALHC since 2021. Their most recent trade was a sale of 25,125 shares, made on Mar 18, 2026. Their largest trade was a sale of 25,125 shares, made on Mar 18, 2026. We estimate that they now own 348,589 shares of $ALHC, worth an estimated $6.2 million.
Insider Trading at $ALHC
There have been a total of 355 insider trades reported at $ALHC since 2021, with 203,000 shares purchased and 152.4 million shares sold. The most active insider traders in $ALHC stock have been John E Kao, Robert Thomas Freeman, and Dawn Christine Maroney. The most recent trade was a sale of 15,361 shares reported by Sebastian Burzacchi (COO - Mgmt Services Org), made on Mar 18, 2026.
History of Insider Stock Trades by Christopher J Joyce
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
ALHC
|
Sale | 25,125 | Mar 18, 2026 | March 19, 2026, 6:40 p.m. |
ALHC
|
Sale | 10,611 | Jan 02, 2026 | Jan. 6, 2026, 7:18 p.m. |
ALHC
|
Sale | 15,299 | Dec 29, 2025 | Dec. 30, 2025, 5:20 p.m. |
ALHC
|
Sale | 888 | Dec 29, 2025 | Dec. 30, 2025, 5:20 p.m. |
ALHC
|
Sale | 19,706 | Dec 08, 2025 | Dec. 8, 2025, 7:26 p.m. |
ALHC
|
Sale | 22,128 | Sep 10, 2025 | Sept. 10, 2025, 8:11 p.m. |
ALHC
|
Sale | 8,811 | Sep 10, 2025 | Sept. 10, 2025, 8:11 p.m. |
ALHC
|
Sale | 15,491 | Jul 31, 2025 | Aug. 1, 2025, 6:28 p.m. |
ALHC
|
Sale | 25,000 | May 01, 2025 | May 2, 2025, 4:29 p.m. |
ALHC
|
Sale | 25,000 | Apr 01, 2025 | April 2, 2025, 7:05 p.m. |
ALHC
|
Sale | 3,959 | Mar 19, 2025 | March 19, 2025, 9:52 p.m. |
ALHC
|
Sale | 6,725 | Mar 18, 2025 | March 19, 2025, 9:52 p.m. |
ALHC
|
Sale | 7,057 | Mar 19, 2025 | March 19, 2025, 9:52 p.m. |
ALHC
|
Sale | 10,871 | Mar 06, 2025 | March 6, 2025, 8:25 p.m. |
ALHC
|
Sale | 25,000 | Mar 04, 2025 | March 6, 2025, 8:25 p.m. |
ALHC
|
Sale | 667 | Oct 01, 2024 | Oct. 3, 2024, 6:19 p.m. |
ALHC
|
Sale | 24,467 | Sep 11, 2024 | Sept. 13, 2024, 6:22 p.m. |
ALHC
|
Sale | 10,159 | Sep 11, 2024 | Sept. 13, 2024, 6:22 p.m. |
ALHC
|
Sale | 4,541 | Sep 05, 2024 | Sept. 6, 2024, 5:29 p.m. |
ALHC
|
Sale | 1,300 | Sep 04, 2024 | Sept. 6, 2024, 5:29 p.m. |
ALHC
|
Sale | 100 | Aug 02, 2024 | Aug. 6, 2024, 6:13 p.m. |
ALHC
|
Sale | 1,233 | Aug 02, 2024 | Aug. 6, 2024, 6:13 p.m. |
ALHC
|
Sale | 15,034 | Jul 15, 2024 | July 16, 2024, 4:30 p.m. |
ALHC
|
Sale | 300 | Jul 12, 2024 | July 16, 2024, 4:30 p.m. |
ALHC
|
Sale | 666 | Jul 01, 2024 | July 3, 2024, 5:37 p.m. |
ALHC
|
Sale | 16,000 | Jun 14, 2024 | June 17, 2024, 8:29 p.m. |
ALHC
|
Sale | 25,060 | Mar 19, 2024 | March 21, 2024, 5 p.m. |
ALHC
|
Sale | 15,474 | Sep 13, 2023 | Sept. 15, 2023, 5 p.m. |
AHCO
|
Sale | 100,000 | Aug 16, 2022 | Aug. 23, 2022, 5:55 p.m. |
$ALHC Executives and Stock Owners with Insider Trades
-
John E Kao, Chief Executive Officer
-
Robert Thomas Freeman, Chief Financial Officer
-
Dawn Christine Maroney, President, Markets
-
Dawn Christine Maroney, President
-
Christopher J Joyce, Chief Legal and Admin. Officer
-
Dinesh M. Kumar, Chief Med & Operating Officer
-
Hyong Kim, Chief Medical Officer
-
Robert L. Scavo, Chief Information Officer
-
Hakan Kardes, Chief Experience Officer
-
Andreas P. Wagner, Chief Human Resources Officer
-
Sebastian Burzacchi, COO - Mgmt Services Org
-
Dinesh M. Kumar, Chief Medical Officer
-
Joseph S Konowiecki, Chairman of the Board
-
Richard A. Cross, SVP, General Counsel
-
Donald Steven Furman, Chief Clinical Officer
-
Rajesh Shrestha, Pres., New Markets & CBO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.